In this paper, an overview of the pharmacokinetics of currently available antiretroviral drugs is provided. Included in this article are the agents zidovudine, stavudine, zalcitabine, lamivudine, didanosine, abacavir, nevirapine, delavirdine, efavirenz, saquinavir, indinavir, ritonavir and nelfinavir. Key pharmacokinetic parameters, drug penetration in body compartments and drug interactions are discussed for each agent.
References
1.
PernoC-F, CooneyD.A., GaoW-Y, HaoZ., JohnsD.G., FoliA., HartmanN.R., Cali'oR., BroderS., & YarchoanR.Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages. Blood1992; 80: 995–1003.
2.
GaoW-Y, ShirasakaT., JohnsD.G., BroderS., & MitsuyaH.Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. Journal of Clinical Investigation1993; 91: 2326–2333.
3.
YarchoanR., KleckerR.W., WeinholdK.J., MarkhamP.D., LyerlyH.K., DurackD.T., GelmannE., LehrmannS.N., BlumR.M., & BarryD.W.Administration of 3′-azido-3′-deox)'thymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet1986; 1: 575–580.
4.
KleckerR.W., CollinsJ.M., YarchoanR., ThomasR., JenkinsJ.F., BroderS., & MyersC.E.Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clinical Pharmacology and Therapy1987; 41: 407–412.
5.
LangtryH.D., & Campoli-RichardsD.M.Zidovudine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs1989; 37: 408–450.
6.
AndersonD.J., O'BrienT.R., PolitchJ.A., MartinezA., SeageG.R., PadianN., HorsburghC.R., & MayerK.H.Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. Journal of the American Medical Association1992; 267: 2769–2774.
7.
RolinskiB., WintergerstU., MatuschkeA., FuesselH., GoebelF.D., RoscherA.A., & BelohradskyB.H.Evaluation of saliva as specimen for monitoring zidovudine therapy in HIV-infected patients. AIDS1990; 5: 885–888.
8.
WattsD.H., BrownZ.A., TartaglioneT., BurchettS.K., OpheimK., CoombsR.R., & CoreyL.Pharmacokinetic disposition of zidovudine during pregnancy. Journal of Infectious Diseases1991; 163: 226–232.
9.
UnadkatJ.D., CollierA.C., CrosbyS.S., CummingsD., OpheimK.E., & CoreyL.Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. AIDS1990; 4: 229–232.
10.
LottererE., RuhnkeM., TrautmannM., BeyerR., & BauerF.E.Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal. European Journal of Clinical Pharmacology1991; 40: 305–308.
11.
SahaiJ., GallicanoK., GarberC., McGilverayI., Hawley-FossN., TurgeonN., & CameronD.W.The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients. British Journal of Clinical Pharmacology1992; 33: 657–660.
12.
RuhnkeM., BauerF.E., SeifertM., TrautmannM., HilleH., & KoeppeP.Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. Antimicrobial Agents and Chemotherapy1993; 37: 2153–2158.
13.
MacNabK.A., GillM.J., SutherlandL.R., De Boer VisserN., & ChurchD.Erratic bioavailability of zidovudine in HIV seropositive patients. Journal of Antimicrobial Chemotherapy1993; 31: 421–428.
14.
StaggM.P., CrettonE.M., KiddL., DiasioR.B., & SommadossiJ-PClinical pharmacokinetics of 3'azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic metabolite, 3′-amino-3′-deoxythymidine. Clinical Pharmacology and Therapeutics1992; 51: 668–676.
15.
HoetelmansR.M.W., KraaijeveldC.L., MeenhorstP.L., MulderJ.W., BurgerD.M., KoksC.H.W., & BeijnenJ.H.Penetration of 3′-amino-3′-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1–infected patients. Journal of Acquired. Immune Deficiency Syndromes and Human Retrovirology1997; 15: 131–136.
16.
HoetelmansR.M.W., BurgerD.M., MeenhorstP.L., & BeijnenJ.H.Pharmacokinetic individuahsation of zidovudine therapy: current state of pharmacokinetic-pharmacodynamic relationships. Clinical Pharmacokinetics1996; 30: 314–327.
17.
MarongiuM.E., AugustE.M., & PrusoffW.H.Effect of 3′-deoxythymidin-2′-ene (d4T) on nucleoside metabolism in H9 cells. Biochemical Pharmacology1990; 39: 1523–1528.
18.
FurmanP.A., FyfeJ.A., St ClairM.H., WeinholdK., RodeoutJ.L., FreemanG.A., LehrmanS.N., BolognesiD.P., BroderS., & MitsuyaH.Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proceedings of the National Academy of Sciences, USA1986; 83: 8333–8337.
19.
DudleyM.N., GrahamK.K., KaulS., GeletkoS., DunkleL., BrowneM., & MayerK.Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. Journal of Infectious Diseases1992; 166: 480–485.
20.
HortonC.M., DudleyM.N., KaulS., MayerK.H., SquiresK., DunkleL., & AndersonR.Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrobiology Agents and Chemotherapy1995; 39: 2309–2315.
21.
DudleyM.N., GeletkoS., GrahamK.K.Bioavailability of high-dose 2’,3′-didehydro-3′-deoxythymidine (d4T) in patients with HIV-infection. Pharmacotherapy1991; 11: 265.
22.
MacleodC.M., BartleyE.A., PaulS.K.Effect of food on oral absorption of stavudine. Journal of Clinical Pharmacology1994; 34: 1025.
23.
FoudraineN.A., HoetelmansR.M.W., LangeJ.M.A., De WolfF., Van BenthemB.H.B., MaasJ., KeetI.P.M., & PortegiesP.Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet1998; 351: 1547–1551.
24.
BawdonR.E., KaulS., & SobhiS.The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. Gynecologic and Obstetric Investigation1994; 38: 1–4.
25.
OdinecsA., NosbischC., KellerR.D., BaughmanW.L., & UnadkatJ.D.In vivo maternal-fetal pharmacokinetics of stavudine (2’,3′-didehydro-3′-deoxythymidine) in pigtailed macaques (Macaca nemestrina). Antimicrobial Agents and Chemotherapy1996; 40: 196–202.
26.
ZhuZ., HoH-T, HitchcockM.J., & SommadossiJ.P.Cellular pharmacology of 2’,3′-didehydro-2’,3′-dideoxythymidine (d4T) in human peripheral blood mononuclear cells. Biochemical Pharmacology1990; 39: R15–R19.
27.
LeaA.P., & FauldsD.Stavudine. A review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drags1996; 51: 846–864.
28.
PettyB., GraselaD., SchaadH.Safety and pharmacokinetics (PK) of stavudine (d4T) in hepatic impairment.2nd National Conference on Human Retroviruses and Related Infections, January 29 - February 2, 1995. Abstract 146.
29.
CooneyD.A., DalaiM., MitsuyaH., McMahonJ.B., NadkarniM., BalzariniJ., BroderS., & JohnsD.G.Initial studies on the cellular pharmacology of 2’,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochemical Pharmacology1986; 35: 2065–2068.
30.
GustavsonL.E., FukudaE.K., RubioF.A., & DuntonA.W.A pilot study of the bioavailability and pharmacokinetics of 2’,3′-dideoxycytidine in patients with AIDS or AIDS-related complex. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1990; 3: 28–31.
31.
KleckerR.W., CollinsJ.M., YarchoanR.C., ThomasR., McAteeN., BroderS., & MyersC.E.Pharmacokinetics of 2’,3′-dideoxycytidine in patients with AIDS and related disorders. Journal of Clinical Pharmacology1988; 28: 837–842.
32.
NazarenoL.A., HolazoA.A., LimjucoR.The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients. Pharmaceutical Research1995; 12: 1462–1465.
33.
YarchoanR., PernoC.F., ThomasR.V., KleckerR.W., AllainJ.P., WillsR.J., McAteeN., FischlM.A., DubinskyR., & McNeelyM.C.Phase I studies of 2’,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet1988; 1: 76–81.
34.
AdkinsJ.C., PetersD.H., & FauldsD.Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs1997; 53: 1054–1080.
35.
Gould ChadwickE., NazarenoL.A., NieuwenhuisT.J., MassarellaJ.W., de DennisS.R., WilliamsK., & YogevR.Phase I evaluation of zalcitabine administered to human immunodeficiency virus-infected children. Journal of Infectious Diseases1995; 172: 1475–1479.
36.
PizzoP.A., ButlerK., BalisF., BrouwersE., HawkinsM., EddyJ., EinlothM., FalloonJ., HussonR., & JarosinskiP.Dideoxycytidine alone and in alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. Journal of Pediatrics1990; 117: 799–808.
37.
MassarellaJ.W., HolazoA.A., Koss-TwardyS.The effects of cimetidine and Maalox on the pharmacokinetics of zalcitabine in HIV-positive patients. Pharmaceutical Research1994; 11(Suppl): S415.
38.
GaoW., AgbariaR., DriscollJ.S., & MitsuyaH.Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2’,3′-dideoxynucleoside analogs in resting and activated human cells. Journal of Biological Chemistry1994; 269: 12633–12638.
39.
SoudeynsH., YaoX-J, GaoQ., BelleauB., KrausJ.L., Nguyen-BaN., SpiraB., & WainbergM.A.Anti-human immunodeficiency type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrobial Agents and Chemotherapy1991; 35: 1386–1390.
40.
CoatesJ.A.V., CammackN., JenkinsonH.J., MuttonI.M., PearsonB.A., StorerR., CameronJ.M., & PennC.R.The sepa rated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro.Antimicrobial Agents and Chemotherapy1992; 36: 202–205.
41.
SchinaziR.F., ChuC.K., PeckA., McMillanA., MathisR., CannonD., JeongL.S., BeachJ.W., ChoiW.B., & YeolaS.Activities of four optical isomers of 2’,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrobial Agents and Chemotherapy1992; 36: 672–676.
42.
HartmanN.R., YarchoanR., PludaJ.M., ThomasR.V., MarczykK.S., BroderS., JohnsD.G.Pharmacokinetics of 2’,3′-dideoxyadenosine and 2’,3′-dideoxyinosine in patients with severe HIV infection. Clinical Pharmacology and Therapeutics1990; 47: 647–654.
43.
ShyuW.C., KnuppC.A., PittmanK.A., DunkleL., & BarbhaiyaR.H.Food induced reduction in bioavailability of didanosine. Clinical Pharmacology and Therapeutics1991; 50: 503–507.
44.
KnuppC.A., ShyuW.C., DolinR., ValentineF.T., McLarenC., MartinR.R., PittmanK.A., & BarbhaiyaR.H.Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome-related complex. Clinical Pharmacology and Therapeutics1991; 49: 523–535.
45.
BalisF.M., PizzoR.A., ButlerK.M., HawkinsM.E., BrouwersP., HussonR.N., JacobsenF., BlaneyS.M., GressJ., & JarosinskiP.Clinical pharmacology of 2’,3′-dideoxyinosine in human immunodeficiency virus-infected children. Journal of Infectious Diseases1992; 165: 99–104.
46.
HoetelmansR.M.W., Van HeeswijkR.P.G., ProfijtM., MulderJ.W., MeenhorstP.L., LangeJ.M.A., ReissP., & BeijnenJ.H.Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected patients. AIDS1998; 12: F211–F216.
47.
BurgerD.M., KraaijeveldC.L., MeenhorstP.L., MulderJ.W., HoetelmansR.M.W., KoksC.H.W., & BeijnenJ.H.Study on didanosine concentrations in cerebrospinal fluid: implications for the treatment and prevention of AIDS dementia complex. Pharmacy World and Science1995; 17: 218–221.
48.
FalettoM.B., MillerW.H., GarveyE.P., St ClairM.H., DalugeS.M., & GoodS.S.Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrobial Agents and Chemotherapy1997; 41: 1099–1107.
49.
DalugeS.M., GoodS.S., FalettoM.B., MillerW.H., St. ClairM.H., BooneL.R., TisdaleM., ParryN.R., ReardonJ.E., DornsifeR.E., AverettD.R., & KrenitskyT.A.1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrobial Agents and Chemotherapy1997; 41: 1082–1093.
50.
GoodS.S., OwensB.S., FalettoM.B.Disposition in monkeys and mice of (1S, 4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-l-methanol (1592U89) succinate, a potent inhibitor of HIV.34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994, Orlando, Fla., USA. Abstract 186.
51.
McDowellJ.A., SymondsW.T., KumarP.N.Initial phase I study of anti-HIV agent 1592U89 in a single-dose escalation design including food effect and dosage form evaluation.35th Interscience Conference on Antimicrobial Agents and. Chemotherapy, 1995, San Francisco, Calif., USA. Abstract 1109.
52.
RavitchJ.R., JarrettJ.L., WhiteH.R.Central nervous system penetration of the antiretroviral abacavir (1592U89) in human and animal models.5th Conference on Retroviruses and Opportunistic Infections, 1998, Chicago, Ill., USA. Poster 636.
53.
Anonymous.Viramune product monograph, version 2.1, Boehringer Ingelheim.
54.
YazdanianM., RatiganS., JosephD.Nevirapine, a non-nucleoside RT inhibitor, readily permeates the blood brain barrier.4th Conference on Retroviruses and Opportunistic Infections, 1997, Washington, DC, USA. Abstract 567.
55.
MirochnikM., and ACTG Protocol 250 Team. Safety and pharmacokinetics (PK) of nevirapine (NVP) in neonates born to HIV-1-infected women.4th Conference on Retroviruses and Opportunistic Infections, 1997, Washington, DC, USA. Abstract 723.
56.
MorseG.D., FischlM.A., SheltonM.J., CoxS.R., DriverM., DeRemerM., & FreimuthW.W.Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy1991; 41: 169–174.
57.
Pharmacia and Upjohn, data on file, November 22, 1996.
58.
DuPont Pharmaceuticals, prescribing information efavirenz (Sustiva), September 1998.
59.
HoetelmansR.M.W., MeenhorstP.L., MulderJ.W., BurgerD.M., KoksC.H.W., BeijnenJ.H.Clinical pharmacology of protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharmacy World Science1997; 19: 159–175.
60.
NobleS., & FauldsD.Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs1996; 52: 93–112.
61.
WilliamsP.E.O., SampsonA.P., GreenC.P.Disposition and bioavailability of the HIV-proteinase inhibitor, Ro 31-8959, after single doses in healthy volunteers. British Journal of Clinical Pharmacology1992; 34: 155P–156P.
62.
MuirheadG.J., ShawT., WilliamsP.E.O.Pharmacokinetics of the HIV-proteinase inhibitor, Ro 31-8959, after single and multiple oral doses in healthy volunteers. British Journal of Clinical Pharmacology1992; 34: 170P–171P.
63.
ShawT.M., MuirheadG.J., ParishN.Tolerability and pharmacokinetics of single oral doses of Ro 31–8959, an HIV proteinase inhibitor. British Journal of Clinical Pharmacology1994; 34: 166P–167P.
64.
MoyleG., & GazzardB.Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs1996; 51: 701–712.
65.
FarrarG., MitchellA.M., HooperH.Prediction of potential drug interactions of saquinavir (Ro 31-8959) from in vitro data. British Journal of Clinical Pharmacology1994; 38: 162P.
66.
KodjoA., DumitrescuL., CrivatM.Digestive absorption of saquinavir in AIDS patients with severe diarrhea or wasting syndrome.3rd International Congress on Drug Therapy in HIV Infection, Birmingham, England, November 1996. P24.
67.
BurgerD.M., HoetelmansR.M.W., KoopmansP.P., MeenhorstP.L., MulderJ.W., HeksterY.A., & BeijnenJ.H.Clinically relevant drug interactions with antiretroviral agents. Antiviral Therapy19972: 149–165.
68.
VaccaJ.P., GuareJ.P., de SolmsS.J., SandersW.M., GiulianiE.A., YoungS.D., DarkeP.L., ZugayJ., SigalI.S., & SchliefW.A.L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. Journal of Medicinal Chemistry1991; 34: 1225–1228.
69.
LyleT.A., WiscountC.M., & GuareJ.P.Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors. Journal of Medicinal Chemistry1991; 34: 1228–1230.
70.
DorseyB.D., LevinR.B., McDanielS.L., VaccaJ.P., GuareJ.P., DarkeJ.P., ZugayJ.A., EminiE.A., SchleifW.A., & QuinteroJ.C.L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. Journal of Medicinal Chemistry1994; 37: 3443–3451.
71.
VaccaJ.P., DorseyB.D., SchleifW.A., LevinR.B., McDanielS.L., DarkeP.L., ZugayJ., QuinteroJ.C., BlahyO.M., & RothE.L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proceedings of the National Academy of Sciences, USA1994; 90: 4096–4100.
72.
SteinD.S., FishD.G., BilelloJ.A.A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS1996; 10: 485–492.
73.
BalaniS.K., ArisonB.H., MathaiL.Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metabolism and Disposition1995; 23: 266–270.
74.
HsuA., GrannemanR., RynkiewiczK.Kinetics of ABT-538, a protease inhibitor, in humans after single oral rising doses.American Association of Pharmaceutical Scientists 9th Annual Meeting & Exposition, April 6–10, 1994, San Diego, Calif., USA. PPDM 8272.
75.
Committee for Proprietary Medicinal Products.European Public Assessment Report (EPAR). Norvir. 16 August 1996, CPMP/527/96.
76.
DannerS.A., CarrA., LeonardJ.M.A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. New England Journal of Medicine1995; 333: 1528–1533.
77.
BertzR., ShiH., CavanaughJ.Effect of three vehicles, Advera®, Ensure®, and chocolate milk, on the bioavailability of an oral liquid formulation of Norvir® (ritonavir).36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La., USA. September 15–19, 1996. A25.
78.
QuartB.D., ChapmanS.K., PeterkinJ.Phase I safety, tolerance, pharmacokinetics and food effect studies of AG1343 – a novel HIV protease inhibitor.2nd National Conference on Human Retroviruses and Related Infections, January 29–February 2, 1995. Abstract 167.
79.
PedneaultL., ElionR., AdlerM.A pilot study of safety and antiviral activity of the combination of sravudine, didanosine and nelfinavir in HIV-infected subjects. AIDS1996; 10(Suppl 2): 17.
80.
JarvisB., & FauldsD.Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs1998; 56: 147–167.
81.
ZhangK., WuE., PatickA.Plasma metabolites of nelfinavir, a potent HIV protease inhibitor, in HIV positive patients: quantitation by LC-MS/MS and antiviral activities. 6th ISSX meeting, 1997, Gottenburg, Sweden. Abstract 128.
